Newsroom

Industry News

14 Feb

Nephros Announces Appointment of Andrew Astor as Chief Financial Officer

RIVER EDGE, NJ–(Marketwired – Feb 14, 2017) – Nephros, Inc. ( OTCQB : NEPH ) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of...

Read more

14 Feb

Catalyst Biosciences Highlights Hemophilia Clinical Development Plans at the 19th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, provided an update on its clinical development plans for its next-generation Factor VIIa and Factor IX candidates and reiterated its intention to...

Read more

13 Feb

Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China

PLYMOUTH MEETING, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human...

Read more

13 Feb

Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma

NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Sandesh Seth, Actinium’s Executive Chairman, will be presenting at the BIO CEO & Investor Conference being...

Read more

13 Feb

Nemus Bioscience Reports Favorable Bio-distribution and Anti-Addictive Findings Versus Plant-Derived Cannabidiol (CBD) in Animal Model Studies of NB2111, an Analogue of Cannabidiol

COSTA MESA, CA / ACCESSWIRE / February 13, 2017 / NEMUS Bioscience, Inc. (NMUS) announced that the company and its research and development partner, the University of Mississippi School of Pharmacy (UM), have conducted in vitro and in vivo bio-distribution and anti-addictive studies of NB2111, a unique analogue of...

Read more

13 Feb

PixarBio Corporation to Attend and Discuss NeuroRelease™ a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 BIO CEO & Investor Conference in NYC, NY, February 13-14, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation (PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018 for our 14-day post-surgical pain treatment, announced today that it will be attending the BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New...

Read more

13 Feb

Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy

LOS ANGELES, CA–(Marketwired – Feb 13, 2017) – Ritter Pharmaceuticals, Inc. ( NASDAQ : RTTR ) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with Dr. B Brett Finlay from...

Read more

10 Feb

Intellipharmaceutics Announces 2016 Year End Results

TORONTO, Feb. 10, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30,...

Read more

9 Feb

Moleculin Announces Pricing of $5 Million Underwritten Public Offering

HOUSTON, TX–(Marketwired – February 09, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center,...

Read more

Page 3 of 21612345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address